0000000000770720

AUTHOR

Ina Haendle

showing 2 related works from this author

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived…

2000

Abstract Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to five biweekly vaccinations of mature, monocyte-derived DC (three vaccinations of 6 × 106 s.c. followed by two i.v. ones of 6 and 12 × 106, respectively) pulsed with Mage-3A2.1 tumor and influenza matrix A2.1-positive control peptides as well as the recall Ag tetanus toxoid (in three of eight patients) generated in all eight patients Ag-specific effector CD8+ T cells that were detectable in blood directly ex vivo. This is the first time …

CD4-Positive T-LymphocytesCytotoxicity Immunologicmedicine.medical_treatmentInjections SubcutaneousImmunologyImmunization SecondaryEpitopes T-LymphocyteCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesMonocytesViral Matrix ProteinsAntigens NeoplasmTetanus ToxoidImmunology and AllergyMedicineCytotoxic T cellHumansMelanomaCells Culturedbusiness.industryMelanomaToxoidCell DifferentiationDendritic cellDendritic Cellsmedicine.diseaseNeoplasm ProteinsImmunizationImmunologyInjections IntravenousIntercellular Signaling Peptides and ProteinsbusinessPeptidesAdjuvantCD8Ex vivoT-Lymphocytes Cytotoxic
researchProduct

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some M…

1999

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin, 3 × 106 DCs each subcutaneously and intradermally, followed by two intravenous injections of 6 × 106 and 12 × 106 DCs, respectively. Only minor (less than or equal to grade II) side effects were observed. Immunity t…

AdultMaleLung NeoplasmsImmunologyCD8-Positive T-LymphocytesTuberculincytotoxic T lymphocytesCancer VaccinesMonocytesLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens NeoplasmTetanus ToxoidmelanomaHumansImmunology and AllergyMedicineCytotoxic T celldendritic cellsNeoplasm MetastasisLymph nodeImmunization ScheduleAgedNeoplasm Stagingactive immunotherapybusiness.industryMelanomaDendritic cellMiddle Agedvaccinationmedicine.diseaseTumor antigenNeoplasm Proteinsmedicine.anatomical_structureImmunologyFemaleOriginal ArticlebusinessCD8T-Lymphocytes CytotoxicJournal of Experimental Medicine
researchProduct